We want to make patients aware that there are global problems with the availability and supply of a range of medication used to treat ADHD. This is an issue beyond the control of Primary care and pharmacy services.
The supply disruption of these products is caused by a combination of manufacturing issues and an increase in demand to manage ADHD. At present we do not know when these issues are likely to resolve.
Medications affected by the supply issues are:
Methylphenidate:
Equasym XL®10, 20 and 30 mg capsules
Xaggitin XL®18 and 36 mg prolonged-release tablets
Concerta XL®54 mg prolonged-release tablets
Xenidate XL®27 mg prolonged-release tablets
Lisdexamfetamine:
Elvanse®20, 30, 40, 50, 60 and 70 mg capsules
Elvanse®Adult 30, 50, and 70 mg capsules
Guanfacine:
Intuniv®1, 2, 3 and 4 mg prolonged-release tablets
If you are affected by these supply issues you would need to contact the service who initiated your medications i.e. the Community Mental Health Team, CAHMS, SAANS or other private providers.